Memantine
Treatment for Alzheimers Disease
Typical Dosage: 5-20 mg orally daily
Effectiveness
40%
Safety Score
68%
Clinical Trials
73
Participants
12K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
5-20 mg orally daily
Time to Effect
2-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$400
Side Effect Mgmt:$50
Total Annual:$550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$2,200
Memantine Outcomes
for Alzheimers Disease
Efficacy Outcomes
Overall Effectiveness
+40%
Response Rate
+25%
Common Side Effects
Dizziness
+7%
Headache
+6%
Confusion
+5%
Constipation
+5%
Sources:
Active Clinical Trials
2 active trials recruiting for Memantine in Alzheimers Disease
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
NCT07251023RECRUITINGPHASE3
450 participants
INTERVENTIONAL
Kazan', Russia +11 more
Started: Nov 20, 2025
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856ACTIVE NOT RECRUITINGPHASE4
53 participants
INTERVENTIONAL
San Diego, United States
Started: Jan 31, 2019
Completed Clinical Trials
13 completed trials for Memantine in Alzheimers Disease
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153COMPLETEDPHASE3
677 participants
INTERVENTIONAL
Phoenix, United States +82 more
Started: Jun 1, 2005
Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer
NCT02553928COMPLETEDPHASE4
62 participants
INTERVENTIONAL
Beijing, China +5 more
Started: Oct 1, 2015
Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease
NCT00800709COMPLETEDPHASE4
26 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 1, 2008
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
NCT03802162COMPLETEDPHASE1
60 participants
INTERVENTIONAL
Seoul, South Korea
Started: Feb 15, 2019
Memantine and Validation of a New Alzheimer's Disease Scale
NCT00804271COMPLETEDPHASE3
487 participants
INTERVENTIONAL
Dresden, Germany
Started: Dec 1, 2008
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease
NCT00097916COMPLETEDPHASE3
34 participants
INTERVENTIONAL
San Francisco, United States +8 more
Started: Sep 1, 2004
Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)
NCT00334906COMPLETEDPHASE4
75 participants
INTERVENTIONAL
Jersey City, United States
Started: Jul 1, 2005
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
NCT00551161COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Manhasset, United States
Started: Aug 1, 2007
Memantine for Agitation and Aggression in Severe Alzheimer's Disease
NCT00401167COMPLETEDPHASE4
31 participants
INTERVENTIONAL
Toronto, Canada +1 more
Started: Nov 1, 2006
Memantine - Communication Study
NCT00624026COMPLETEDPHASE3
107 participants
INTERVENTIONAL
Frankfurt am Main, Germany
Started: Nov 1, 2007
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
NCT00476008COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Boca Raton, United States
Started: Jul 1, 2007
Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease
NCT00469456COMPLETEDPHASE4
265 participants
INTERVENTIONAL
East Gosford, Australia +24 more
Started: Apr 1, 2007
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608COMPLETEDPHASE4
17 participants
INTERVENTIONAL
New York, United States
Started: Jul 1, 2009
Showing 20 of 73 total trials